Abstract:Objective: To summarize the conclusions of an expert panel of neurologists specializing in multiple sclerosis (MS) convened for the purpose of creating a treatment algorithm with regard to the clinical management of MS. The panel was sponsored by the Health Science Center for Continuing Medical Education and the University of Medicine and Dentistry of New Jersey and supported by an educational grant from Biogen Idec, Inc. Summary: MS is a chronic demyelinating disease characterized by a variable clinical course. Currently, there is no cure for MS, and the management of MS requires lifelong treatment with disease-modifying agents. Some patients respond well to therapy for many years, whereas others may have aggressive disease that is more difficult to manage. Hence, given the variable nature in the course of MS and patients. response to treatment, neurologists must individualize care for their patients. An MS treatment algorithm was recently developed by a panel of neurologists who are MS experts to provide community neurologists with best-practice protocols for treating and managing their MS patients. The panel of experts categorized MS into 3 different stages, with patients transitioning between the stages based on their response to therapy and disease progression. Stage I represents MS early in the progression of the disease, during which platform drug therapy is recommended (i.e., interferon beta-1b [IFNbeta-1b], IFNbeta-1a, or glatiramer acetate). The results of randomized, controlled clinical trials suggest that IFNbeta is the optimal choice for platform therapy. Despite treatment with platform therapy, it is common for patients to experience some ongoing symptoms and periodic exacerbations of the disease (annual relapse rate of 0.59 to 0.84 on treatment); such relapses should not be considered treatment failures and are best managed with steroids. Stage II represents acute breakthrough disease (i.e., when the clinical activity becomes more frequent or severe). This stage is best managed by the addition of pulse corticosteroids to the platform drug. Stage III represents continued breakthrough disease and is best managed by the addition of immunosuppressants to the platform drug. Conclusion: The MS treatment algorithm provides an educational resource for physicians. It should assist all health care professionals involved in the management of MS patients and enhance their ability to improve quality of life for these patients over the course of the disease.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists

Newer agents in the treatment of multiple sclerosis

Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges

Current and emerging therapies in multiple sclerosis: a systematic review

Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action

Therapeutic developments in multiple sclerosis

Multiple sclerosis: therapeutic update

Immunological Aspects of Approved MS Therapeutics

Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches

Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis

Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis

Progressive multiple sclerosis: latest therapeutic developments and future directions

Disease Modifying Therapy in Progressive Multiple Sclerosis：A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Multiple sclerosis. Recent modalities of treatment

Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

[Treatments for multiple sclerosis: update]

A review of possible therapies for multiple sclerosis

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management

Investigational drug therapies of treatment of multiple sclerosis